Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system
S Puglisi, A Rossini, R Poli, F Dughera, A Pia… - Frontiers in …, 2021 - frontiersin.org
Sodium-glucose cotransporters inhibitors (SGLT2-i) and GLP-1 receptor agonists (GLP1-
RA) are glucose-lowering drugs that are proved to reduce the cardiovascular (CV) risk in …
RA) are glucose-lowering drugs that are proved to reduce the cardiovascular (CV) risk in …
Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT …
BA Borlaug, MR Zile, CM Kramer, SJ Baum, K Hurt… - Nature Medicine, 2024 - nature.com
Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) display
circulatory volume expansion and pressure overload contributing to cardiovascular–kidney …
circulatory volume expansion and pressure overload contributing to cardiovascular–kidney …
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
Cardiovascular and renal outcome trials (CVOTs) for glucagon-like-peptide-1 receptor
agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) highlight new …
agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) highlight new …
The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function
M Wajdlich, M Nowicki - Scientific Reports, 2024 - nature.com
Chronic treatment with GLP-1R agonists may moderately lower blood pressure due to
increased natriuresis and RAAS inhibition. Short-term effect of these drugs on blood …
increased natriuresis and RAAS inhibition. Short-term effect of these drugs on blood …
Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms
Type 2 diabetes mellitus (T2DM) is highly prevalent and associated with a two-fold
increased mortality, mostly explained by cardiovascular diseases. Trial evidence on older …
increased mortality, mostly explained by cardiovascular diseases. Trial evidence on older …
Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone that has undergone a revolutionary
turnaround from discovery to clinically approved therapeutic. Rapid progress in drug design …
turnaround from discovery to clinically approved therapeutic. Rapid progress in drug design …
The GLP-1-mediated gut-kidney cross talk in humans: mechanistic insight
Incretin-based therapy is an antidiabetic and antiobesity approach mimicking glucagon-like
peptide-1 (GLP-1) with additional end-organ protection. This review solely focuses on …
peptide-1 (GLP-1) with additional end-organ protection. This review solely focuses on …
Bidirectional relation between dipeptidyl peptidase 4 and angiotensin II type I receptor signaling
FL Martins, JC Ribeiro-Silva… - American Journal of …, 2024 - journals.physiology.org
Cardiometabolic diseases are often associated with heightened levels of angiotensin II (Ang
II), which accounts for the observed oxidative stress, inflammation, and fibrosis …
II), which accounts for the observed oxidative stress, inflammation, and fibrosis …
Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists
P Trevella, EI Ekinci, RJ MacIsaac - Nephrology, 2024 - Wiley Online Library
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention
for their potential benefits in people with type 2 diabetes (T2DM) with chronic kidney disease …
for their potential benefits in people with type 2 diabetes (T2DM) with chronic kidney disease …
GLP− 1 promotes cortical and medullary perfusion in the human kidney and maintains renal oxygenation during NaCl loading
B Haddock, KB Kristensen, M Tayyab… - Journal of the …, 2023 - ahajournals.org
Background GLP‐1 (glucagon‐like peptide‐1) receptor agonists exert beneficial long‐term
effects on cardiovascular and renal outcomes. In humans, the natriuretic effect of GLP‐1 …
effects on cardiovascular and renal outcomes. In humans, the natriuretic effect of GLP‐1 …